Literature DB >> 18339192

Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective.

Holly R Martin1, Michele D Poe, Debra Reinhartsen, Rebecca E Pretzel, Jackson Roush, Angela Rosenberg, Stacey C Dusing, Maria L Escolar.   

Abstract

UNLABELLED: Lysosomal storage diseases and related disorders (LSRDs) are a heterogeneous group of rare diseases caused by genetic mutations that result in deficiencies of specific lysosomal enzymes. Some of these enzymes are necessary for normal development of the central and peripheral nervous systems. Because of the heterogeneity in clinical presentation and complexity of these disorders, evaluation of disease progression poses unique challenges. In recent years, recombinant enzyme replacement therapy and haematopoietic stem cell transplantation have been developed to treat some of these diseases. With the development of specific therapies and screening programmes, there is a need to systematically follow the natural course and effects of treatment in these disorders with standardized and validated tools. This review describes the limitations of currently available neurobehavioural tools in longitudinally tracking disease outcomes in patients with neurodegenerative LSRDs. A multidisciplinary team reviewed over 750 evaluations in 274 patients. These patients were found to have neurological, sensory and somatic problems that considerably influence the results of neurobehavioural testing.
CONCLUSION: Treatment effects in patients with neurodegenerative LSRDs are best evaluated by repeated measures and longitudinal analysis of each domain of function.

Entities:  

Mesh:

Year:  2008        PMID: 18339192     DOI: 10.1111/j.1651-2227.2008.00651.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  14 in total

1.  Cognitive Development in a Young Child with Mucolipidosis Type IV: A Case Report.

Authors:  Evelyn L Fisher; Rose A Sevcik; MaryAnn Romski
Journal:  JIMD Rep       Date:  2017-01-03

2.  Midbrain morphology reflects extent of brain damage in Krabbe disease.

Authors:  Giulio Zuccoli; Srikala Narayanan; Ashok Panigrahy; Michele D Poe; Maria L Escolar
Journal:  Neuroradiology       Date:  2015-04-10       Impact factor: 2.804

3.  Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.

Authors:  Elsa G Shapiro; Igor Nestrasil; Kyle Rudser; Kathleen Delaney; Victor Kovac; Alia Ahmed; Brianna Yund; Paul J Orchard; Julie Eisengart; Gregory R Niklason; Julian Raiman; Eva Mamak; Morton J Cowan; Mara Bailey-Olson; Paul Harmatz; Suma P Shankar; Stephanie Cagle; Nadia Ali; Robert D Steiner; Jeffrey Wozniak; Kelvin O Lim; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2015-06-17       Impact factor: 4.797

4.  Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome.

Authors:  Kathleen A Delaney; Kyle R Rudser; Brianna D Yund; Chester B Whitley; Patrick A J Haslett; Elsa G Shapiro
Journal:  JIMD Rep       Date:  2013-11-05

5.  Spontaneous Third Ventriculostomy in Krabbe Disease.

Authors:  Giulio Zuccoli; Aram Kim; Michele Poe; Maria L Escolar
Journal:  Pediatr Neurol       Date:  2019-12-02       Impact factor: 3.372

6.  Long-term neurodevelopmental outcomes of hematopoietic stem cell transplantation for late-infantile Krabbe disease.

Authors:  Isabel C Yoon; Nicholas A Bascou; Michele D Poe; Paul Szabolcs; Maria L Escolar
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113

7.  Natural history of Sanfilippo syndrome type A.

Authors:  Dakota Buhrman; Kavita Thakkar; Michele Poe; Maria L Escolar
Journal:  J Inherit Metab Dis       Date:  2013-11-23       Impact factor: 4.982

8.  Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.

Authors:  Maurizio Scarpa; Zsuzsanna Almássy; Michael Beck; Olaf Bodamer; Iain A Bruce; Linda De Meirleir; Nathalie Guffon; Encarna Guillén-Navarro; Pauline Hensman; Simon Jones; Wolfgang Kamin; Christoph Kampmann; Christina Lampe; Christine A Lavery; Elisa Leão Teles; Bianca Link; Allan M Lund; Gunilla Malm; Susanne Pitz; Michael Rothera; Catherine Stewart; Anna Tylki-Szymańska; Ans van der Ploeg; Robert Walker; Jiri Zeman; James E Wraith
Journal:  Orphanet J Rare Dis       Date:  2011-11-07       Impact factor: 4.123

9.  Early disease progression of Hurler syndrome.

Authors:  Bridget T Kiely; Jennifer L Kohler; Hannah Y Coletti; Michele D Poe; Maria L Escolar
Journal:  Orphanet J Rare Dis       Date:  2017-02-14       Impact factor: 4.123

10.  Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III.

Authors:  Arunabha Ghosh; Elsa Shapiro; Stewart Rust; Kathleen Delaney; Samantha Parker; Adam J Shaywitz; Adelaida Morte; Gillian Bubb; Maureen Cleary; Tien Bo; Christine Lavery; Brian W Bigger; Simon A Jones
Journal:  Orphanet J Rare Dis       Date:  2017-06-26       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.